Cargando…
Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis
BACKGROUND: Red blood cell distribution width (RDW), a biomarker for discrimination of anemia, has been recently identified as a prognostic factor in various types of cancer. Here we performed a meta-analysis in order to assess the correlation between RDW and the survival outcomes in patients with h...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914059/ https://www.ncbi.nlm.nih.gov/pubmed/29713244 http://dx.doi.org/10.1186/s12935-018-0558-3 |
_version_ | 1783316642208415744 |
---|---|
author | Ai, Lisha Mu, Shidai Hu, Yu |
author_facet | Ai, Lisha Mu, Shidai Hu, Yu |
author_sort | Ai, Lisha |
collection | PubMed |
description | BACKGROUND: Red blood cell distribution width (RDW), a biomarker for discrimination of anemia, has been recently identified as a prognostic factor in various types of cancer. Here we performed a meta-analysis in order to assess the correlation between RDW and the survival outcomes in patients with hematologic malignances. PATIENTS/METHODS: We systematically searched PubMed, Embase, and ISI Web of Science for relevant studies, to investigate the prognostic significance of RDW in hematological malignancies. Odds ratios or hazards ratios (HRs) with corresponding 95% confidence intervals (CIs) are pooled to estimate the association between RDW and clinicopathological parameters of patients with hematologic malignances. RESULTS: Seven trials with 1031 patients suffering from hematological malignancies were included in the meta-analysis, and the results indicated that increased pretreatment RDW predicted poor overall survival (HR = 2.35, 95% CI 1.70–3.24), poor progress-free survival (HR = 2.44, 95% CI 1.70–3.49) and poor event-free survival (EFS) (HR = 3.15, 95% CI 1.59–6.25). Furthermore, the similar results were observed in subgroup analysis stratified by cancer type, such as multiple myeloma, and diffuse large B cell lymphoma, etc. CONCLUSIONS: As for hematologic malignances, patients with higher RDW are more likely to have poorer prognosis than those with lower RDW. |
format | Online Article Text |
id | pubmed-5914059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59140592018-04-30 Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis Ai, Lisha Mu, Shidai Hu, Yu Cancer Cell Int Primary Research BACKGROUND: Red blood cell distribution width (RDW), a biomarker for discrimination of anemia, has been recently identified as a prognostic factor in various types of cancer. Here we performed a meta-analysis in order to assess the correlation between RDW and the survival outcomes in patients with hematologic malignances. PATIENTS/METHODS: We systematically searched PubMed, Embase, and ISI Web of Science for relevant studies, to investigate the prognostic significance of RDW in hematological malignancies. Odds ratios or hazards ratios (HRs) with corresponding 95% confidence intervals (CIs) are pooled to estimate the association between RDW and clinicopathological parameters of patients with hematologic malignances. RESULTS: Seven trials with 1031 patients suffering from hematological malignancies were included in the meta-analysis, and the results indicated that increased pretreatment RDW predicted poor overall survival (HR = 2.35, 95% CI 1.70–3.24), poor progress-free survival (HR = 2.44, 95% CI 1.70–3.49) and poor event-free survival (EFS) (HR = 3.15, 95% CI 1.59–6.25). Furthermore, the similar results were observed in subgroup analysis stratified by cancer type, such as multiple myeloma, and diffuse large B cell lymphoma, etc. CONCLUSIONS: As for hematologic malignances, patients with higher RDW are more likely to have poorer prognosis than those with lower RDW. BioMed Central 2018-04-23 /pmc/articles/PMC5914059/ /pubmed/29713244 http://dx.doi.org/10.1186/s12935-018-0558-3 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Primary Research Ai, Lisha Mu, Shidai Hu, Yu Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis |
title | Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis |
title_full | Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis |
title_fullStr | Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis |
title_full_unstemmed | Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis |
title_short | Prognostic role of RDW in hematological malignancies: a systematic review and meta-analysis |
title_sort | prognostic role of rdw in hematological malignancies: a systematic review and meta-analysis |
topic | Primary Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914059/ https://www.ncbi.nlm.nih.gov/pubmed/29713244 http://dx.doi.org/10.1186/s12935-018-0558-3 |
work_keys_str_mv | AT ailisha prognosticroleofrdwinhematologicalmalignanciesasystematicreviewandmetaanalysis AT mushidai prognosticroleofrdwinhematologicalmalignanciesasystematicreviewandmetaanalysis AT huyu prognosticroleofrdwinhematologicalmalignanciesasystematicreviewandmetaanalysis |